Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once-weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1-5, 7-10 and SUSTAIN China.
Li-Nong JiA J AhmannBo AhrénM S CapehornP HuIldiko LingvayW LiuHelena W RodbardZ ShenC SorliPublished in: Diabetes, obesity & metabolism (2023)
Treatment with OW SC semaglutide versus comparators was associated with increased proportions of participants with T2D meeting the composite metabolic endpoint.
Keyphrases